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Abstract
Background: We attempted to describe the clinical features and determine the factors associated with renal
survival in idiopathic membranous nephropathy (iMN) patients with nephrotic syndrome (NS) and to determine the
factors associated with spontaneous complete remission (sCR) and progression to NS in iMN patients with
subnephrotic proteinuria.
Methods: This retrospective study involved 166 iMN patients with NS and 65 patients with subnephrotic proteinuria.
The primary end point was a doubling of serum creatinine or initiation of dialysis. In patients with subnephrotic
proteinuria, we determined the factors associated with sCR and factors associated with progression to NS.
Results: Remission of NS was achieved in 125 out of 166 patients (75.3%). Of those who reached remission, 26 patients
(20.8%) experienced relapse that was followed by second remission. The relapse or persistence of proteinuria was
associated with the primary end points (hazard ratio [HR] = 12.40, P = 0.037, HR = 173, P < 0.001, respectively). In
patients with subnephrotic proteinuria, sCR occurred in 35.4% of the patients. The patients with sCR had lower
proteinuria and serum creatinine levels and higher serum albumin concentrations at baseline. The serum albumin level
at diagnosis was a prognostic factor for progression to NS (Odds ratio [OR] = 0.015, P < 0.001).
Conclusions: The occurrence of relapse or persistence of proteinuria had negative effects on renal survival in iMN patients
with NS, and low serum albumin levels at baseline were associated with non-achievement of sCR and progression to NS.
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Background
Idiopathic membranous nephropathy (iMN) is the most
common cause of adult onset nephrotic syndrome (NS)
[1, 2]. Clinical presentations of iMN vary from
subnephrotic-range proteinuria regarded as asymptom-
atic urinary abnormality to NS with heavy proteinuria.
From the studies on the natural history of iMN, it was
suggested that many untreated patients had stable renal
function and possibility of spontaneous remission [3].
Approximately one-third of the patients experience
spontaneous remission, another third show persistent
proteinuria, and the remaining third progress to end-
stage renal disease (ESRD). Approximately 20–30% of
untreated iMN patients progress to ESRD [4]. These
variable courses of iMN lead to great difficulties when
physicians need to decide the treatment regimen.
Many researchers have attempted to identify the risk
factors for poor prognosis. Several studies showed that male
sex, old age (>50 years old), hypertension, massive protein-
uria (>10 g/24 h), and elevated serum creatinine concentra-
tion at the time of renal biopsy are poor prognostic factors
of iMN [5–8]. Also, Polanco et al. reported that spontan-
eous remission was predicted based on baseline serum
creatinine levels and proteinuria extent, treatment with
angiotensin-converting enzyme inhibitors or angiotensin-
receptor antagonists, and a >50% decline in proteinuria
from baseline during the first year of follow-up [9]. Among
these factors, persistent heavy proteinuria was the most
reliable predictor of life-threatening complications and poor
renal outcomes in iMN patients. On the basis of these
results, aggressive treatments have been introduced to
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induce complete or partial remission or to reduce the
amount of proteinuria in patients with poor prognostic
factors.
Not only the aforementioned demographic and laboratory
parameters at diagnosis but also response to treatment
could be major predictors of renal survival. In patients with
NS, whether remission is achieved or not could affect long-
term outcomes [10]. The patients who had subnephrotic-
range proteinuria during the observation period had better
outcomes than patients who progressed from subnephrotic-
range proteinuria to nephrotic-range proteinuria [11].
Despite we consider the proteinuria levels as an import-
ant prognostic factor, it is still uncertain whether relapse
or persistence of proteinuria has a negative impact on
long-term renal outcomes in iMN patients. Therefore, we
performed a retrospective study to describe the clinical
features and determine the factors associated with renal
survival in iMN patients with NS and to determine the
factors associated with spontaneous complete remission
(sCR) and progression to NS in iMN patients with
subnephrotic-range proteinuria. Besides determining the
prognostic factors, we also expected to gain additional
information regarding differences according to geograph-
ical regions or populations.
Methods
Study population
We attempted to recruit biopsy-proven adult iMN patients
by reviewing medical records from the archives of the
Department of Pathology at the Seoul National University
Hospital. Patients with systemic diseases such as rheumatic
diseases, malignant tumours, or infections with hepatitis B
or C virus, and other diseases associated with secondary
membranous nephropathy (MN) were excluded. From
January 1989 to December 2012, a total of 231 patients
were diagnosed with idiopathic or primary MN through
renal biopsy. We classified the patients into 2 groups
according to the level of proteinuria at the time of renal
biopsy. Of them, 65 patients (28.1% of total patients)
presented with subnephrotic range proteinuria, and 166
patients (71.9%) had NS that was defined as proteinuria of
3.5 g/day (or urine protein:creatinine ratio [uPCR] 3.5 g/g)
or more and the presence of hypoalbuminemia.
Study design
Information regarding the demographic, clinical, and
laboratory variables was collected via medical record re-
view. We determined the factors affecting the long-term
outcomes separately according to the groups. First, con-
cerning patients with NS, we analysed the factors affecting
the renal survival including the impact of relapse or persist-
ence of proteinuria. Second, in patients with subnephrotic-
range proteinuria, we evaluated the factors predicting spon-
taneous remission of proteinuria or progression to NS. The
primary outcome was the doubling of serum creatinine
concentration or development of ESRD in iMN patients
with NS or subnephrotic proteinuria. The secondary out-
come was sCR or progression to NS in iMN patients with
subnephrotic-range proteinuria.
Definition
We adopted the definition of the KDIGO practice guideline
on glomerulonephritis, presented in 2012 [12]. Complete
remission (CR) was defined as urinary protein excretion
<0.3 g/day (uPCR < 0.3 g/g) confirmed by 2 values at least
1 week apart, accompanied by normal serum albumin
concentration and normal serum creatinine level. Partial
remission (PR) was defined as urinary protein excretion
<3.5 g/day (uPCR < 3.5 g/g) and ≥50% reduction from the
peak values confirmed by 2 values at least 1 week apart,
accompanied by an improvement or normalisation of the
serum albumin concentration and stable serum creatinine
level. In addition, we defined proteinuria less than 0.3 g/day
(uPCR < 3.5 g/g) as subnephrotic-range proteinuria and a
case that meets aforementioned conditions of remission
without using immunosuppressive agents as sCR. The
patients who showed spontaneous PR or reached remission
through immunosuppressive therapy were not considered
as having sCR. After remission was achieved, urinary
protein excretion >0.3 g/day (uPCR > 0.3 g/g) in CR or
≥50% increase in the lowest values in patients with PR
confirmed by 2 values at least 1 week apart with or without
decline of serum albumin concentration and/or rise of
serum creatinine was defined as relapse. The progression to
NS was defined as development of NS in patients who had
subnephrotic-range proteinuria at the time of diagnosis.
Statistical analysis
Numerical variables were expressed as the mean ± standard
deviation (SD), and non-parametric variables were
expressed as median and range. For group comparisons, 2-
sample t-test, Mann-Whitney U test, analysis of variance
(ANOVA), and Kruskal-Wallis test were applied. Categor-
ical variables were expressed as numbers and percentages
and compared using the χ2 test or Fisher’s exact test. Renal
event-free survival rate was calculated by the Kaplan-Meier
method. The difference in survival rates between groups
was examined by the log-rank test. The relationship of the
covariates to renal survival was evaluated using the Cox
proportional hazards model, yielding the hazard ratio (HR)
and 95% confidence interval. Additionally, to assess the
effects of variables on sCR or progression to NS in
subnephrotic-range proteinuria patients, univariate and
multivariate logistic regression analyses were conducted,
yielding unadjusted odds ratio (OR) and adjusted OR, re-
spectively. Analyses were performed using the IBM SPSS
statistics (version 21.0, Chicago, IL, USA). All tests were 2-
tailed, with P < 0.05 considered statistically significant.
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Results
Patients with NS
The baseline characteristics of the patients with NS are
listed in Table 1. In all, 32 (19.4%) patients had an esti-
mated glomerular filtration rate (eGFR) lower than
60 mL · min−1 · 1.73 m−2 at diagnosis. Seventy (42.2%)
patients presented with heavy proteinuria (>8 g/g
creatinine) and only 13 (7.8%) patients presented with
urinary protein excretion <4 g/g creatinine at the time of
renal biopsy. The median follow-up duration was
123 months (67–199). Renin-angiotensin-aldosterone
system (RAAS) blockades, other anti-hypertensive
agents (including beta-blockers and calcium channel
blockers), and HMG-CoA reductase inhibitors (statins)
were used for conservative management in 126 (75.9),
82 (49.4), and 123 (74.1%) patients, respectively. Conser-
vative measures comprised RAAS blockades, and other
non-immunosuppressive agents were applied to 30
(18.1%) patients. Although immunosuppressive regimens
were not uniform according to the different therapeutic
protocols, 136 (81.9%) patients were treated with im-
munosuppressive agents (Table 2).
Remission of NS was achieved in 125 (75.3%) of 166
NS patients. Among the remission-induced patients, 75
(60.0%) patients maintained remission until the end of
the follow-up period. Twenty-six (20.8%) patients experi-
enced relapse of proteinuria: 2 in the conservative treat-
ment group, 3 in the corticosteroids alone group, 16 in
the corticosteroid plus cyclophosphamide group, and 5
in the corticosteroid plus cyclosporine group (Table 2).
After the first relapse occurred, second-line immunosup-
pressive agents induced second remission in all the
patients. Of the 30 patients that were managed conser-
vatively, 26 (86.7%) patients achieved spontaneous re-
mission. The remaining 4 patients did not achieve
remission and had persistent proteinuria. Although the
patients treated conservatively seemed to have had bet-
ter prognosis, we should consider the disease severity at
baseline. The conservatively treated patients had signifi-
cantly lower proteinuria (P = 0.018) and higher serum
albumin concentration (P < 0.001) than the groups
treated with immunosuppressive agents (Table 2).
The primary composite end-point, defined as the
doubling of serum creatinine or development of ESRD,
occurred in 22 (13.3%) patients. As shown in Table 3, on
adjusting for age, gender, systolic blood pressure, serum
creatinine, serum albumin, and proteinuria level, patients
who experienced relapse showed poor outcomes (Hazard
ratio [HR] = 12.40, P = 0.037). Furthermore, iMN patients
who did not achieve remission had poorer long-term out-
comes (HR = 173, P <0.001). The event-free renal survival
rate was very good in patients with persistent remission.
However, the survival rate was the poorest in patients who
never reached remission. The patients who experienced
relapse had intermediate long-term prognosis (Fig. 1).
Patients with subnephrotic range proteinuria
The baseline characteristics are listed in Table 1. Even in
this group, 9 patients had decreased renal function (eGFR
< 60 mL ·min−1 · 1.73 m−2). The sCR was achieved in 23
(35.4%) patients. There were significant differences in
serum albumin concentration, serum cholesterol level, and
level of proteinuria between the sCR group and those who
did not reach sCR (Table 4). Progression to NS occurred in
26 patients among 65 subnephrotic patients. Among sCR-
achieved 23 patients, NS developed only in 2 patients, and
among non-sCR-induced 42 patients, NS developed in 24
patients. On comparing patients with progression to NS
and those with non-progression, the serum albumin levels
were found to be low, and the serum cholesterol concentra-
tions and proteinuria level, high (Table 5).
In the non-sCR group or patients with progression to
NS, the most commonly used immunosuppressive regimen
was combined corticosteroid and cyclophosphamide (in 22
patients). In addition, oral corticosteroid (4 patients) and
corticosteroid combined with cyclosporine (3 patients) were
used for treatment. The outcomes of treatments were
similar to those of NS patients at baseline [CR in 23
(79.3%) patients, PR in 2 (8.6%) patients]. Primary compos-
ite end points developed in 3 (4.6%) patients from the
non-sCR group and they also had advanced chronic kidney
disease stage with low eGFR at baseline. Therefore, they







Age (years) 53 ± 13 49 ± 12
BMI (kg/m2) 24.52 ± 2.90 23.65 ± 2.66
Male 103 (62%) 32 (49.8%)
SBP (mmHg) 130 ± 19 123 ± 14
DBP (mmHg) 82 ± 12 79 ± 8
Serum creatinine (mg/dl) 0.99 ± 0.39 1.03 ± 0.65
CKD stage according to eGFR
Stage I 61 (37%) 28 (43.1%)
Stage II 72 (43.6%) 28 (43.1%)
Stage III – V 32 (19.4%) 9 (13.9%)
Serum albumin (g/dl) 2.41 ± 0.55 3.17 ± 0.70
Proteinuria (g/g creatinine) 8.18 (5.10–10.35) 2.11 (1.88–2.32)
> 8 70 (42.2%) –
4–8 72 (43.4%) –
< 4 13 (7.8%) 65
Data are presented as means ± SD, number (% of total) or median (range)
SD Standard deviation, BMI Body mass index, SBP Systolic blood pressure, DBP
Diastolic blood pressure, CKD Chronic kidney disease, eGFR estimated
glomerular filtration rate, estimated with Modification of Diet in Renal
Disease equation
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were treated only with conservative management. The pa-
tients who achieved sCR had excellent prognosis and did
not show any primary composite outcomes. Although pro-
gression to NS occurred in 2 patients in this sCR group,
CR was induced with immunosuppressive treatment.
In the logistic regression analyses, serum creatinine and
albumin concentrations and the amount of proteinuria at
the time of renal biopsy were the significant factors for
sCR. Low serum albumin levels at baseline were associ-
ated with non-achievement of sCR and high serum albu-
min levels at baseline were associated with sCR (Odds
ratio [OR] = 7.78, P = 0.010) (Table 6). Furthermore, low
serum albumin concentrations at baseline were associated
with progression to NS (OR = 0.015, P < 0.001, Table 7).
Discussion
In this study, we performed a retrospective investigation
to evaluate the effect of response to therapy on the long-
term renal function in iMN patients with NS and to deter-
mine the prognostic factors in patients with subnephrotic
proteinuria. In NS patients, the relapse or persistence of
proteinuria was associated with a poor renal survival rate.
Furthermore, in the subnephrotic proteinuria patients
group, sCR occurred frequently in patients with low pro-
teinuria and serum creatinine levels and with higher
serum albumin concentrations at baseline. Furthermore,
the serum albumin level at diagnosis was the strongest
prognostic factor for progression to NS.







cyclophosphamide (N = 100)
Oral corticosteroid +
cyclosporine (N = 14)
Agea (years) 51 47 57 44
SBP (mmHg) 128 125 130 135
Proteinuriaa(g/g creatinine) 6.43 6.95 8.93 8.53
Serum Albumina(g/dL) 2.8 2.5 2.3 2.3
Serum creatinine (mg/dl) 0.91 0.93 1.03 0.92
Total cholesterola(mg/dl) 277 354 354 321
Treatments
RAAS blockers 26 (86.7%) 13 (59.1%) 75 (75%) 12 (85.7%)
Anti-HTN 13 (43.3%) 11 (50%) 51 (51%) 7 (50%)
Statin 22 (73.3%) 10 (45.5%) 79 (79%) 12 (85.7%)
Remission 26 (86.7%) 17 (77.2%) 73 (73%) 9 (64.3%)
Relapse 2/26 (7.7%) 3/17 (17.6%) 16/73 (21.9%) 5/9 (55.6%)
Persistence 4 (13.4%) 5 (22.8%) 27 (27%) 5 (35.7%)
End pointsb 2 (6.7%) 4 (18.2%) 13 (13%) 3 (21.4%)
Data are presented as mean, number (% of total)
aP < 0.01, Difference between groups; RAAS blockers Renin-angiotensin-aldosterone system blockers, Anti-HTN Anti-hypertensive medication
bEnd points include doubling of serum creatinine concentration compared to baseline level and development of end stage renal disease
Table 3 Multivariate Cox proportional hazards model for ESRD
or doubling of serum creatinine in patients with nephrotic
syndrome
Hazard ratio P- value
Relapse 12.40 (1.17–131.6) 0.037
Persistence 173 (11.2–2660) 0.001
Adjusted for age, gender, Systolic blood pressure, serum creatinine
concentration, serum albumin concentration, serum cholesterol concentration,
and quantity of urine protein
Fig. 1 Kaplan-Meier curve of event-free renal survival according to
the clinical courses in patients with nephrotic syndrome (P < 0.001)
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In iMN patients, the conventionally accepted clinical
course is that one-third tend to have spontaneous remis-
sion, one-third, progressive renal failure, and one-third,
stable renal function. In the modern era, the manage-
ment of iMN has been modified. Anti-proteinuric ther-
apies such as RAAS blockades and strict blood pressure
control have been used widely, and there have been sig-
nificant advances in immunosuppressive therapy [13].
Although definite evidences regarding whether RAAS
blockades contribute to remission are lacking [10], the
probability of spontaneous remission seems to be high
in patients treated with RAAS blockades [14]. Also, the
Ponticelli regimen comprising alkylating agents and cor-
ticosteroids and the Cattran regimen comprising cyclo-
sporine and low-dose corticosteroid have been found to
be beneficial for the induction of remission and reducing
Table 4 Comparisons of clinical characteristics according to the spontaneous complete remission in patients with subnephrotic
range proteinuria
Spontaneous CR (N = 23) No spontaneous CRa (N = 42) P-value
Male 12 (52.2%) 20 (47.6%) 0.463
Age (years) 46 ± 13 51 ± 11 0.065
BMI (kg/m2) 23.9 ± 3.2 23.5 ± 2.4 0.501
Hypertension 3 (13%) 13 (31%) 0.109
Serum creatinine (mg/dl) 0.90 ± 0.18 1.11 ± 0.80 0.230
Serum albumin (g/dl) 3.58 ± 0.52 2.95 ± 0.68 <0.001
Serum cholesterol (mg/dl) 217.7 ± 64.0 264.3 ± 92.1 0.043
CKD stage according to eGFR 0.103
Stage I 10 (43.5%) 18 (42.9%)
Stage II 13 (56.5%) 15 (35.7%)
Stage III – 5 (11.9%)
Stage IV-V – 4 (9.6%)
Serum hemoglobin (g/dL) 13.6 ± 1.6 12.6 ± 2.2 0.074
Proteinuria (g/g creatinine) 1.68 ± 0.88 2.36 ± 0.81 0.003
BMI Body mass index, CKD Chronic kidney disease, eGFR estimated glomerular filtration rate, estimated with Modification of Diet in Renal Disease
aGroup of ‘No spontaneous CR’ include patients that had spontaneous partial remission or remission through immunosuppressant
Data are presented as number (% of total) or means ± SD
Table 5 Comparisons of clinical characteristics according to disease progression in patients with subnephrotic range proteinuria
Progression to NS (N = 26) No progressiona (N = 39) P-value
Male 9 (34.6%) 23 (58.9%) 0.124
Age (years) 53 ± 11 47 ± 13 0.088
BMI (kg/m2) 23.5 ± 2.3 23.9 ± 2.8 0.513
Hypertension 8 (28.6%) 8 (20.5%) 0.558
Serum creatinine (mg/dl) 0.90 ± 0.18 1.11 ± 0.80 0.230
Serum albumin (g/dl) 2.67 ± 0.61 3.36 ± 0.48 <0.001
Serum cholesterol (mg/dl) 274.1 ± 92.4 225.3 ± 62.4 0.018
CKD stage according to eGFR 0.399
Stage I 14 (53.8%) 14 (35.9%)
Stage II 10 (38.5%) 18 (46.1%)
Stage III 1 4 (10.3%)
Stage IV-V 1 3 (7.7%)
Serum hemoglobin (g/dL) 12.4 ± 2.2 13.4 ± 1.9 0.073
Proteinuria (g/g creatinine) 2.46 ± 0.73 1.83 ± 0.92 0.005
Data are presented as number (% of total) or means ± SD
BMI Body mass index, CKD Chronic kidney disease, eGFR estimated glomerular filtration rate, estimated with Modification of Diet in Renal Disease, NS
nephrotic syndrome
aGroup of ‘No progression’ include patients that had spontaneous remission or remission through immunosuppressant or stable status of disease
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the requirement for renal replacement therapy (RRT)
[15–17]. Subsequently, many randomised controlled tri-
als have been published. A meta-analysis showed that a
combination of alkylating agents and corticosteroids re-
duced the risk of ESRD and all-cause mortality [18].
Paradoxically, variable courses of iMN and proven bene-
fits of aggressive therapy make it difficult for physicians
to choose the appropriate treatment regimen. Although
per the KDIGO guidelines, immunosuppressive agents
are recommended considering the amount and duration
of proteinuria, it is uncertain whether relapse of protein-
uria has a negative effect on long-term renal outcomes.
Also, management protocols according to the thera-
peutic response have not yet been established.
Our data showed better prognosis with regard to the
remission rate and requirement for RRT than other
studies. McQuarrie et al. reported that 76% of the pa-
tients achieved at least one PR in 5 years after diagnosis,
32.8% experienced relapse, and 11.9% required RRT [10].
Although the remission rate was similar to that in our
study, the probability of relapse in this study (20.8%) was
low. The cause of improved outcomes in our study is
unclear and might have resulted from the frequent use
of RAAS blockades (75.9%) and immunosuppressive
therapies (81.9%). Otherwise, it may support the theory
that the clinical course in Asian patients is benign as
compared to that in the Caucasian population [19–21].
Through analyses of patients presenting with NS, we
showed that maintenance of remission state is important
for the preservation of long-term renal function. In
previous reports, there was a good chance of achieving
second remission with treatment even in the relapsed
patients, and the prognosis was good compared to the
excellent prognosis of persistent remission [10, 22, 23].
Furthermore, because patients showing persistence of
proteinuria (defined as no response to treatment in
other studies) had poorer renal outcomes than patients
who experienced relapse and subsequent remission, it
should be emphasised that maintaining remission is im-
portant for achieving a favourable long-term outcome. If
our results are verified through additional studies, this
would affect the clinical decision process regarding the
therapeutic regimens. Although the relapse rate was not
significantly different for the immunosuppressive agents
in this study, it seemed high in the patient group treated
with cyclosporine (55.6%) [24]. These possibilities should
make physicians pay close attention when choosing im-
munosuppressive agents, especially for patients with risk
factors that affect the long-term renal outcomes.
The sCR was achieved in 26 patients out of 166 patients
with NS (15.7%). All the sCR-induced patients have been
treated conservatively because of the favorable initial pres-
entation. In NS patients who were treated conservatively
without remission induction therapy (30 patients), the pa-
rameters reflecting disease severity were advantageous
compared to the patients treated with immunosuppressive
agents (136 patients). In patients with subnephrotic range
proteinuria, the rate of sCR was 35.4% (23 patients out of
65 patients). The initial parameters associated with out-
comes were more favorable in patients with subnephrotic
proteinuria who did not reach sCR compared to sCR-
achieved NS patients. We could explain this discrepancy
as a factor of renal function. In patients with subnephrotic
proteinuria without sCR, the initial serum creatinine was
1.11 mg/dl. It might reflect an advanced stage of iMN.
Therefore, the sCR might not occur in these patients des-
pite of other favorable factors.
In patients with subnephrotic proteinuria, we attempted
to create a statistical model that can predict the possibility
of spontaneous remission or progression to NS using lo-
gistic regression analyses. We found that serum albumin
concentration had a high predictive value in forecasting
the disease course. Hladunewich et al. reported high pro-
teinuria at baseline in the group that subsequently pro-
gressed to NS [11]. In this study, the proteinuria level was
also low in patients reaching sCR (1.68 ± 0.88 g/g creatin-
ine vs. 2.36 ± 0.81 g/g creatinine, P < 0.003). Furthermore,
proteinuria level was one of the prognostic factors for sCR
in the multivariate analysis. However, this parameter was
not a significant risk factor for progression to NS. This
difference suggests that spot urine measurement of pro-
teinuria cannot fully reflect the clinical course of patients
because of diurnal variation. Otherwise, the result might
Table 6 Logistic regression analyses for spontaneous complete
remission in patients with subnephrotic range proteinuria
Unadjusted OR P-value Adjusted OR P-value
Serum creatinine
(mg/dl)
0.43 (0.10–1.90) 0.265 0.015 (0.1–0.74) 0.032
Serum
albumin (g/dl)




0.99 (0.98–1.00) 0.050 0.99 (0.98–1.00) 0.325
Proteinuria
(g/g creatinine)
0.99 (0.98–1.00) 0.006 0.999 (0.998–1.00) 0.038
Table 7 Logistic regression analyses for progression to nephrotic
syndrome in patients with subnephrotic range proteinuria
Unadjusted OR P-value Adjusted OR P-value
Serum creatinine
(mg/dl)
0.97 (0.37–2.54) 0.954 0.09 (0.03–2.76) 0.168
Serum albumin
(g/dl)
0.31 (0.12–0.79) 0.014 0.015 (0.00–0.15) <0.001
Serum cholesterol
(g/dl)
1.00 (0.99–1.00) 0.050 1.00 (1.00–1.002) 0.314
Proteinuria
(g/g creatinine)
1.00 (1.00–1.002) 0.051 1.00 (1.00–1.001) 0.109
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have simply been achieved because of a small study size.
Serum albumin concentration at the time of diagnosis was
revealed to be the strongest prognostic factor for both
sCR and the progression to NS among the patients with
subnephrotic range proteinuria. We assume that as the
disease courses of iMN are shifting, the level of serum al-
bumin reflect this change much faster than other parame-
ters such as a proteinuria amount or serum cholesterol
concentration. We ought to measure the serum albumin
level serially as well as urine protein in the follow-up of
subnephrotic iMN patients.
In patients with subnephrotic range proteinuria
depicted in Table 5, the patients who progressed to NS
were older and more hypertensive compared to the non-
progression group, but those were not significant statis-
tically. However, the level of total cholesterol and the
amount of daily proteinuria were high in patients with
progression to NS, which were significant statistically.
We consider that the concentrations of serum albumin
and total cholesterol and the amount of proteinuria are
reflecting the severity of iMN. Therefore, their concen-
trations or amount change parallel in concordance with
the disease course. Among the 3 variables, the level of
serum albumin was most useful in the risk stratification
and this was reported previously [25].
This study has several limitations. This was a retrospect-
ive study accomplished with a review of medical records.
Therefore, the interpretation might be biased owing to se-
lection error. Because we included records of patients
from the year 1989, the treatment regimens were quite
different according to the era. Furthermore, there was no
standardised regimen for induction and maintenance ther-
apy, and the treatment decisions were totally dependent
on the preference of individual physicians. Therefore,
these fundamental restrictions could not be avoided in the
evaluation of the effect of each treatment.
Conclusions
We found that the occurrence of relapse or persistence
of proteinuria had a negative impact on renal survival in
iMN patients with nephrotic syndrome. In addition, low
serum albumin levels at baseline were associated with
non-achievement of sCR and progression to NS.
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